Blood cancers are complex and multifaceted diseases, requiring knowledge by healthcare professionals on the array of diagnostic tests, treatment therapies, and survivorship issues. The LLS Podcast Series for Professionals provides up to date and accurate information on diagnosis, treatment and survivorship to educate HCPs treating patients with blood cancer. Listen in as we speak with experts who will guide us in understanding these topics, as well as address the importance of clinical trials, side effects management, and other concerns.
2022 ASH Annual Meeting: Highlights from the Perspective of a Conference Attendee
Lee Greenberger, PhD, The Leukemia & Lymphoma Society, Rye Brook, NY
Recorded on December 19, 2022
Lee Greenberger, PhD
Chief Scientific Officer and SVP
The Leukemia & Lymphoma Society
Rye Brook, NY
In this episode, Lee Greenberger, PhD, Chief Scientific Officer and Senior Vice President at The Leukemia & Lymphoma Society, returns to provide an update on the information presented at the 64th American Society of Hematology (ASH) Annual Meeting, including leukemia, lymphoma, myeloma, MDS, and MPNs. Dr. Greenberger discusses updates in blood cancer therapies, including CAR T-cell therapy, bi-specific antibodies, and vaccine therapy, reviews the latest data on COVID-19, and addresses challenges that exist in diversity and equity in the healthcare system, including ways to overcome these barriers. Tune in today!
Understanding Waldenström Macroglobulinemia
Shayna Sarosiek, MD, Dana Farber Cancer Institute, Boston, MA
Recorded on December 6, 2022
Shayna Sarosiek, MD
Harvard Medical School
Dana Farber Cancer Institute
Waldenström Macroglobulinemia (WM) is a rare blood cell cancer characterized by an excess number of abnormal white blood cells in the bone marrow. How does WM fit into the spectrum of other blood cancer diseases? Who is at risk? What are the genetic factors? Dr. Shayna Sarosiek, from the Dana-Farber Cancer Institute, joins us to provide a deep dive into WM, including testing, monitoring, treatment updates, clinical trials, and so much more. Tune in today!
This activity is developed through a collaboration with the International Waldenström’s Macroglobulinemia Foundation.
CAR T-cell Therapy in Review 2022: Updates in Treatment
Sattva S. Neelapu, MD, M.D. Anderson Cancer Center, Houston, TX
Recorded on December 16, 2022
Sattva S. Neelapu, MD
Professor and Deputy Chair
Department of Lymphoma and Myeloma
The University of Texas M.D. Anderson Cancer Center
Chimeric antigen receptor (CAR) T-cell therapy has generated impressive results in hematologic malignancies, with many drugs still in clinical trials. In this episode, Dr. Sattva S. Neelapu from MD Anderson Cancer Center, joins us to discuss updates on CAR T-cell therapy from the 2022 American Society of Hematology (ASH) Annual Meeting. Dr. Neelapu also provides a high-level overview of how CAR T-cell therapy works, including the manufacturing process, and discusses the risk of recurrence following therapy, risk for patients in the era of COVID-19, secondary cancers, associated costs, roadblocks to therapy, and why early referral matters. Tune in to this informative podcast episode to learn more!
This podcast episode is supported by Allogene Therapeutics, Bristol Myers Squibb, CRISPR Therapeutics, Janssen Oncology & Legend Biotech, Kite, A Gilead Company and Novartis Oncology.
Shared Decision Making with Your Patients Diagnosed with a Chronic Leukemia: Part II
Daphne Friedman, MD, Durham VA Health Care System, Durham, NC
Recorded on October 20, 2022
Daphne Friedman, MD
Staff Oncologist, Durham VA Health Care System
Associate Professor, Duke University School of Medicine
In Part II of Shared Decision Making with Your Patients Diagnosed with a Chronic Leukemia, Dr. Daphne Friedman, from the Durham VA Health Care System in North Carolina, discusses the importance of a relationship between the provider and the patient when it comes to shared decision making (SDM), including the unique conversations of SDM with young adults and with healthcare providers who are patients. Dr. Friedman also shares challenges with seeking a second opinion, relying on information found on the internet, and additional resources. Tune in today to learn more!
This podcast episode is supported by AbbVie Inc. and Genentech, Inc.
AML: Insights, Updates, and Takeaways
Eytan M. Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY
Recorded on October 7, 2022
Eytan M. Stein, MD
Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Associate Attending Physician
Leukemia Service, Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY
Dr. Eytan Stein, from Memorial Sloan Kettering Cancer Center, joins us to reflect on breakthroughs in acute myeloid leukemia, including updates in treatment, long-term and late effects of therapy, and side effect management. Tune in to this episode as Dr. Stein discusses an overview of data presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) as well as updates from The Leukemia & Lymphoma Society’s BEAT AML® Master Trial.
Insights from Attending the 2022 Society of Hematologic Oncology (SOHO) Annual Meeting
Saad Z. Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY
Recorded on September 30, 2022
Saad Z. Usmani, MD, MBA, FACP
Chief, Myeloma Service
Memorial Sloan Kettering Cancer Center
New York, NY
Join us for this special episode, recorded live from the Tenth Annual Meeting of the Society of Hematologic Oncology in Houston, TX! Guest host and conference attendee, Lauren Berger, Senior Director of Professional Education and Engagement at The Leukemia & Lymphoma Society, speaks with Dr. Saad Usmani, from Memorial Sloan Kettering Cancer Center, about his insights into the progress in immunotherapies in blood cancers shared at the conference. Not able to attend SOHO? Learn more about what was shared at the conference by tuning in here!